In our previous study, up-regulation of IGF2 was not observed in HNCHPV− BYL719-acquired resistance cell line models, and supplementation of tumor cells with recombinant IGF was able to achieve a partial rescue to anti-PI3K in two of the five tested cell lines [20]. The gene discussed is IGF1; the disease is neoplasm.